SEARCH

SEARCH BY CITATION

References

  • Al-Mawali, A., Gillis, D., Hissaria, P. & Lewis, I. (2008) Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. American Journal of Clinical Pathology, 129, 934945.
  • Al-Mawali, A., Gillis, D. & Lewis, I. (2009) The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Cytometry. Part B, Clinical Cytometry, 76, 91101.
  • van den Ancker, W., Terwijn, M., Westers, T.M., Merle, P.A., van Beckhoven, E., Dräger, A.M., Ossenkoppele, G.J. & van de Loosdrecht, A.A. (2010) Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification. Leukemia, 24, 13921396.
  • Arroyo, J.L., Fernández, M.E., Hernández, J.M., Orfao, A., San Miguel, J.F. & del Cañizo, M.C. (2004) Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalitie. The Hematology Journal, 5, 227233.
  • Bachas, C., Schuurhuis, G.J., Hollink, I.H., Kwidama, Z.J., Goemans, B.F., Zwaan, C.M., van den Heuvel-Eibrink, M.M., de Bont, E.S., Reinhardt, D., Creutzig, U., de Haas, V., Assaraf, Y.G., Kaspers, G.J. & Cloos, J. (2010) High frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood, 116, 27522758.
  • Baer, M.R., Stewart, C.C., Dodge, R.K., Leget, G., Sulé, N., Mrózek, K., Schiffer, C.A., Powell, B.L., Kolitz, J.E., Moore, J.O., Stone, R.M., Davey, F.R., Carroll, A.J., Larson, R.A. & Bloomfield, C.D. (2001) High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implication for residual disease detection. Blood, 97, 35743580.
  • Bagg, A. (2007) Lineage ambiguity, infidelity, and promiscuity in immunophenotypically complex acute leukemias genetic and morphologic correlates. The American Journal of Pathology, 128, 545548.
  • Basso, G., Case, C. & Dell’Orto, M.C. (2007) Diagnosis and genetic subtypes of leukemia combining gene expression and flow cytometry. Blood Cells, Molecules, and Diseases, 39, 164168.
  • Béné, M.C. (2005) Immunophenotyping of acute leukaemias. Immunology Letters, 98, 921.
  • Béné, M.C. & Kaeda, J.S. (2009) How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet. Haematologica, 94, 11351150.
  • Béné, M.C., Castoldi, G., Knapp, W., Ludwig, W.D., Matutes, E. & Orifao, A. (1995) Proposals for the immunological classification of acute leukemis. European Group for the immunological characterization of leukemias (EGIL). Leukemia, 9, 17831786.
  • Breems, D.A., Van Putten, W.L., De Greef, G.E., Van Zelderen-Bhola, S.L., Gerssen-Schoorl, K.B., Mellink, C.H., Nieuwint, A., Jotterand, M., Hagemeijer, A., Beverloo, H.B. & Löwenberg, B. (2008) Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. Journal of Clinical Oncology, 26, 47914797.
  • Buccisano, F., Maurillo, L. & Gattei, V. (2006) The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia, 20, 17831789.
  • Buccisano, F., Maurillo, L., Spagnoli, A., Del Principe, M.I., Ceresoli, E., Lo Coco, F., Arcese, W., Amadori, S. & Venditti, A. (2009) Monitoring of minimal residual disease in acute myeloid leukemia. Review. Current Opinion in Oncology, 21, 582588.
  • Campana, D. (2003) Determination of minimal residual disease in leukaemia patients. Review. British Journal of Haematology, 121, 823838.
  • ten Cate, B., de Bruyn, M., Wei, Y., Bremer, E. & Helfrich, W. (2010) Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology. Current Drug Targets, 11, 95110. Review.
  • Cesana, C., Klersy, C., Brando, B., Nosari, A., Scarpati, B., Scampini, L., Molteni, A., Nador, G., Santoleri, L., Formenti, M., Valentini, M., Mazzone, A., Morra, E. & Cairoli, R. (2008) Prognostic value of circulating CD34+ cells in myelodysplastic syndromes. Leukemia Research, 32, 17151723.
  • Chang, H., Yeung, J., Brandwein, J. & Yi, Q. (2007) CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype. Leukemia Research, 31, 157162.
  • Cilloni, D., Renneville, A., Hermitte, F., Hills, R.K., Daly, S., Jovanovic, J.V., Gottardi, E., Fava, M., Schnittger, S., Weiss, T., Izzo, B., Nomdedeu, J., van der Heijden, A., van der Reijden, B.A., Jansen, J.H., van der Velden, V.H., Ommen, H., Preudhomme, C., Saglio, G. & Grimwade, D. (2009) Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. Journal of Clinical Oncology, 27, 51955201.
  • Civin, C.I. & Loken, M.R. (1987) Cell surface antigens on human marrow cells: dissection of hematopoietic development using monoclonal antibodies and multiparameter flow cytometry. International Journal of Cell Cloning, 5, 267288.
  • Cloos, J., Goemans, B.F., Hess, C.J., van Oostveen, J.W., Waisfisz, Q., Corthals, S., de Lange, D., Boeckx, N., Hählen, K., Reinhardt, D., Creutzig, U., Schuurhuis, G.J., Zwaan, Ch.M. & Kaspers, G.J. (2006) Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia, 20, 12171220.
  • Coustan-Smith, E., Ribeiro, R.C., Rubnitz, J.E., Razzouk, B.I., Pui, C.H., Pounds, S., Andreansky, M., Behm, F.G., Raimondi, S.C., Shurtleff, S.A., Downing, J.R. & Campana, D. (2003) Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. British Journal of Haematology, 123, 243252.
  • Craig, F.E. & Foon, K.A. (2008) Flow cytometric immunophenotyping for hematologic neoplasms. Blood, 111, 39413967.
  • Del Cañizo, M.C., Fernández, M.E., López, A., Vidriales, B., Villarón, E., Arroyo, J.L., Ortuño, F., Orfao, A. & San Miguel, J.F. (2003) Immunophenotypic analysis of myelodysplastic syndromes. Haematologica, 88, 402407.
  • Díez-Campelo, M., Pérez-Simón, J.A., Pérez, J., Alcoceba, M., Richtmon, J., Vidriales, B. & San Miguel, J. (2009) Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. American Journal of Hematology, 84, 149152.
  • Döhner, H., Estey, E.H., Amadori, S., Appelbaum, F.R., Büchner, T., Burnett, A.K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R.A., Lo-Coco, F., Naoe, T., Niederwieser, D., Ossenkoppele, G.J., Sanz, M.A., Sierra, J., Tallman, M.S., Löwenberg, B. & Bloomfield, C.D. (2010) European Leukemianet diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Review. Blood, 115, 453474.
  • Dunphy, C.H. (1999) Comprehensive review of adult acute myelogenous leukemia: cytomorphological, enzyme cytochemical, flow cytometric immunophenotypic, and cytogenetic findings. Journal of Clinical Laboratory Analysis, 13, 1926.
  • Elghetany, M.T. (2002) Surface antigen changes during normal neutrophilic development: a critical review. Blood Cells, Molecules, and Diseases, 28, 260274.
  • Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., Bigerna, B., Pacini, R., Pucciarini, A., Liso, A., Vignetti, M., Fazi, P., Meani, N., Pettirossi, V., Saglio, G., Mandelli, F., Lo-Coco, F., Pelicci, P.G. & Martelli, M.F. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New England Journal of Medicine, 352, 254256.
  • Feller, N., Schuurhuis, G.J., van der Pol, M.A., Westra, G., Weijers, G.W., van Stijn, A., Huijgens, P.C. & Ossenkoppele, G.J. (2003) High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. Leukemia, 17, 6875.
  • Feller, N., van der Pol, M.A., van Stijn, A., Weijers, G.W., Westra, A.H., Evertse, B.W., Ossenkoppele, G.J. & Schuurhuis, G.J. (2004) MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia, 18, 13801390.
  • Feller, N., Jansen-van der Weide, M.C., van der Pol, M.A., Westra, G.A., Ossenkoppele, G.J. & Schuurhuis, G.J. (2005) Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden. Experimental Hematology, 33, 120130.
  • Gianfaldoni, G., Mannelli, F., Baccini, M., Antonioli, E., Leoni, F. & Bosi, A. (2006) Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study. British Journal of Haematology, 134, 5457.
  • Goardon, N., Nikolousis, E., Sternberg, A., Chu, W.K., Craddock, C., Richardson, P., Benson, R., Drayson, M., Standen, G., Vyas, P. & Freeman, S. (2009) Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes. Haematologica, 94, 11601163.
  • Gorin, N.C., Labopin, M., Reiffers, J., Milpied, N., Blaise, D., Witz, F., de Witte, T., Meloni, G., Attal, M., Bernal, T. & Rocha, V. (2010) Higher incidence of relapse for acute myelocytic leukemia patients infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. Blood, 116, 31573162.
  • Grimwade, D., Jovanovic, J.V., Hills, R.K., Nugent, E.A., Patel, Y., Flora, R., Diverio, D., Jones, K., Aslett, H., Batson, E., Rennie, K., Angell, R., Clark, R.E., Solomon, E., Lo-Coco, F., Wheatley, K. & Burnett, A.K. (2009) Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. Journal of Clinical Oncology, 27, 36503658.
  • Grimwade, D., Vyas, P. & Freeman, S. (2010a) Assessment of minimal residual disease in acute myeloid leukemia. Current Opinion in Oncology, 22, 656663.
  • Grimwade, D., Hills, R.K., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A.H., Wheatley, K., Harrison, C.J. & Burnett, A.K. (2010b) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood, 116, 354365.
  • Gröschel, S., Lugthart, S., Schlenk, R.F., Valk, P.J., Eiwen, K., Goudswaard, C., van Putten, W.J., Kayser, S., Verdonck, L.F., Lübbert, M., Ossenkoppele, G.J., Germing, U., Schmidt-Wolf, I., Schlegelberger, B., Krauter, J., Ganser, A., Döhner, H., Löwenberg, B., Döhner, K. & Delwel, R. (2010) High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. Journal of Clinical Oncology, 28, 21012107.
  • Haferlach, C., Mecucci, C., Schnittger, S., Kohlmann, A., Mancini, M., Cuneo, A., Testoni, N., Rege-Cambrin, G., Santucci, A., Vignetti, M., Fazi, P., Martelli, M.P., Haferlach, T. & Falini, B. (2009) AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood, 114, 30243032.
  • Hanson, C.A., Abaza, M., Sheldon, S., Ross, C.W., Schnitzer, B. & Stoolman, L.M. (1993) Acute biphenotypic leukaemia: immunophenotypic and cytogenetic analysis. British Journal of Haematology, 84, 4960.
  • Hellström-Lindberg, E., Gulbrandsen, N., Lindberg, G., Ahlgren, T., Dahl, I.M., Dybedal, I., Grimfors, G., Hesse-Sundin, E., Hjorth, M., Kanter-Lewensohn, L., Linder, O., Luthman, M., Löfvenberg, E., Oberg, G., Porwit-MacDonald, A., Rådlund, A., Samuelsson, J., Tangen, J.M., Winquist, I. & Wisloff, F.; Scandinavian MDS Group (1997) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodyplastic syndromes: proposal for a predictive model. British Journal of Haematology, 99, 344351.
  • Hellström-Lindberg, E., Gulbrandsen, N., Lindberg, G., Ahlgren, T., Dahl, I.M., Dybedal, I., Grimfors, G., Hesse-Sundin, E., Hjorth, M., Kanter-Lewensohn, L., Linder, O., Luthman, M., Löfvenberg, E., Oberg, G., Porwit-MacDonald, A., Rådlund, A., Samuelsson, J., Tangen, J.M., Winquist, I. & Wisloff, F.A. (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology, 120, 10371046.
  • Hess, C.J., Feller, N., Denkers, F., Kelder, A., Merle, P.A., Heinrich, M.C., Harlow, A., Berkhof, J., Ossenkoppele, G.J., Waisfisz, Q. & Schuurhuis, G.J. (2009) Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia. Haematologica, 94, 4653.
  • Hokland, P., Kerndrup, G., Griffin, J.D. & Ellegaard, J. (1986) Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies. Blood, 67, 898902.
  • Kanda, Y., Hamaki, T., Yamamoto, R., Chizuka, A., Suguro, M., Matsuyama, T., Takezako, N., Miwa, A., Kami, M., Hirai, H. & Togawa, A. (2000) The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: an overview of 2483 patients from 22 studies. Cancer, 88, 25292533.
  • Keating, S., Suciu, S., de Witte, T., Zittoun, R., Mandelli, F., Belhabri, A., Amadori, S., Fibbe, W., Gallo, E., Fillet, G., Varet, B., Meloni, G., Hagemeijer, A., Fazi, P., Solbu, G. & Willemze, R.; EORTC Leukemia Group; GIMEMA Leukemia Group (2003) The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia, 17, 6067.
  • Kern, W., Danhauser-Riedl, S., Ratei, R., Schnittger, S., Schoch, C., Kolb, H.J., Ludwig, W.D., Hiddemann, W. & Haferlach, T. (2003) Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. Haematologica, 88, 646653.
  • Kern, W., Voskova, D., Schoch, C., Hiddeman, W., Schnittger, S. & Haferlach, T. (2004a) Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute leukemia. Blood, 104, 30783085.
  • Kern, W., Voskova, D., Schoch, C., Schnittger, S., Hiddemann, W. & Haferlach, T. (2004b) Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. Haematologica, 89, 528540.
  • Kern, W., Haferlach, C., Haferlach, T. & Schnittger, S. (2008) Monitoring of minimal residual disease in acute myeloid leukemia. Cancer, 112, 416.
  • Kern, W., Haferlach, C., Bacher, U., Haferlach, T. & Schnittger, S. (2009) Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity. Leukemia, 23, 13611364.
  • Khoury, H., Dalal, B.I., Nevill, T.J., Horsman, D.E., Barnett, M.J., Shepherd, J.D., Toze, C.L., Conneally, E.A., Sutherland, H.J., Hogge, D.E. & Nantel, S.H. (2003) Acute myelogenous leukemia with t(8;21) – identification of a specific immunophenotype. Leukaemia & Lymphoma, 44, 17131718.
  • Knipp, S., Strupp, C., Gattermann, N., Hildebrandt, B., Schapira, M., Giagounidis, A., Aul, C., Haas, R. & Germing, U. (2008) Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. Leukemia Research, 32, 3337.
  • Kottaridis, P.D., Gale, R.E., Langabeer, S.E., Frew, M.E., Bowen, D.T. & Linch, D.C. (2002) Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood, 100, 23932398.
  • Krause, D.S. & Van Etten, R.A. (2007) Right on target: eradicating leukemic stem cells. Trends in Molecular Medicine, 13, 470481.
  • Kussick, S.J., Fromm, J.R., Rossini, A., Li, Y., Chang, A., Norwood, T.H. & Wood, B.L. (2005) Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. American Journal of Clinical Pathology, 124, 170181.
  • Laane, E., Derolf, A.R., Björklund, E., Mazur, J., Everaus, H., Söderhäll, S., Björkholm, M. & Porwit-MacDonald, A. (2006) The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica, 91, 833836.
  • Lacombe, F., Arnoulet, C., Maynadié, M., Lippert, E., Luquet, I., Pigneux, A., Vey, N., Casasnovas, O., Witz, F. & Béné, M.C. (2009) Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. Leukemia, 23, 350357.
  • Langebrake, C., Brinkmann, I., Teigler-Schlegel, A., Creutzig, U., Griesinger, F., Puhlmann, U. & Reinhardt, D. (2005) Immunophenotypic differences between diagnosis and relapse in childhood AML: implications for MRD monitoring. Cytometry. Part B, Clinical Cytometry, 63, 19.
  • Langebrake, C., Creutzig, U., Dworzak, M., Hrusak, O., Mejstrikova, E., Griesinger, F., Zimmermann, M. & Reinhardt, D. (2006) Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. Journal of Clinical Oncology, 24, 36863692.
  • Lee, E.J., Yang, L., Leavitt, R.D., Testa, J.R., Civin, C.I. & Forrest, A. (1992) The significance of CD34 and TdT determinations in patients with untreated de novo acute myeloid leukemia. Leukemia, 6, 12031209.
  • Legrand, O., Perrot, J.Y., Simonin, G., Baudard, M., Cadiou, M., Blanc, C., Ramond, S., Viguié, F., Marie, J.P. & Zittoun, R. (1998) Adult biphenotypic acute leukaemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression. British Journal of Haematology, 100, 147155.
  • van Lochem, E.G., van der Velden, V.H., Wind, H.K., te Marvelde, J.G., Westerdaal, N.A. & van Dongen, J.J. (2004) Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related and disease-induced shifts. Cytometry. Part B, Clinical Cytometry, 60, 113.
  • Loken, M.R., van de Loosdrecht, A., Ogata, K., Orfao, A. & Wells, D.A. (2008) Flow cytometry in myelodysplastic syndromes: report from a working conference. Leukemia Research, 32, 517.
  • van de Loosdrecht, A.A., Westers, T.M., Westra, A.H., Dräger, A.M., van der Velden, V.H. & Ossenkoppele, G.J. (2008) Identification of distinct prognostic subgroups in low and intermediate-1 risk myelodysplastic syndromes by flow cytometry. Blood, 111, 10671077.
  • van de Loosdrecht, A.A., Alhan, C., Béné, M.C., Della Porta, M.G., Dräger, A.M., Feuillard, J., Font, P., Germing, U., Haase, D., Homburg, C.H., Ireland, R., Jansen, J.H., Kern, W., Malcovati, L., Te Marvelde, J.G., Mufti, G.J., Ogata, K., Orfao, A., Ossenkoppele, G.J., Porwit, A., Preijers, F.W., Richards, S.J., Schuurhuis, G.J., Subirá, D., Valent, P., van der Velden, V.H., Vyas, P., Westra, A.H., de Witte, T.M., Wells, D.A., Loken, M.R. & Westers, T.M. (2009) Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica, 94, 11241134.
  • Lorand-Metze, I., Califani, S.M., Ribeiro, E., Lima, C.S. & Metze, K. (2008) The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes. Leukemia Research, 32, 211213.
  • Lucio, P., Gaipa, G., van Lochem, E.G., van Wering, E.R., Porwit-MacDonald, A., Faria, T., Bjorklund, E., Biondi, A., van den Beemd, M.W., Baars, E., Vidriales, B., Parreira, A., van Dongen, J.J., San Miguel, J.F. & Orfao, A.; BIOMED-I (2001) BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. Leukemia, 15, 11851192.
  • Malcovati, L., Della Porta, M.G., Lunghi, M., Pascutto, C., Vanelli, L., Travaglino, E., Maffioli, M., Bernasconi, P., Lazzarino, M., Invernizzi, R. & Cazzola, M. (2005a) Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia, 19, 776783.
  • Malcovati, L., Porta, M.G., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., Passamonti, F., Arcaini, L., Maffioli, M., Bernasconi, P., Lazzarino, M. & Cazzola, M. (2005b) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. Journal of Clinical Oncology, 23, 75947603.
  • Marcucci, G., Caligiuri, M.A., Döhner, H., Archer, K.J., Schlenk, R.F., Döhner, K., Maghraby, E.A. & Bloomfield, C.D. (2001) Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia, 15, 10721080.
  • Matarraz, S., López, A., Barrena, S., Fernandez, C., Jensen, E., Flores, J., Bárcena, P., Rasillo, A., Sayagues, J.M., Sánchez, M.L., Hernandez-Campo, P., Hernandez Rivas, J.M., Salvador, C., Fernandez-Mosteirín, N., Giralt, M., Perdiguer, L. & Orfao, A. (2008) The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia, 22, 11751183.
  • Matarraz, S., López, A., Barrena, S., Fernandez, C., Jensen, E., Flores-Montero, J., Rasillo, A., Sayagues, J.M., Sánchez, M.L., Bárcena, P., Hernandez-Rivas, J.M., Salvador, C., Fernandez-Mosteirín, N., Giralt, M., Perdiguer, L., Laranjeira, P., Paiva, A. & Orfao, A. (2010) Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry. Part B, Clinical Cytometry, 78, 154168.
  • Maurillo, L., Buccisano, F., Spagnoli, A., Del Poeta, G., Panetta, P., Neri, B., Del Principe, M.I., Mazzone, C., Consalvo, M.I., Tamburini, A., Ottaviani, L., Fraboni, D., Sarlo, C., De Fabritiis, P., Amadori, S. & Venditti, A. (2007) Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica, 92, 605611.
  • Maurillo, L., Buccisano, F., Del Principe, M.I., Del Poeta, G., Spagnoli, A., Panetta, P., Ammatuna, E., Neri, B., Ottaviani, L., Sarlo, C., Venditti, D., Quaresima, M., Cerretti, R., Rizzo, M., de Fabritiis, P., Lo Coco, F., Arcese, W., Amadori, S. & Venditti, A. (2008) Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. Journal of Clinical Oncology, 26, 49444951.
  • Maynadié, M., Picard, F., Husson, B., Chatelain, B., Cornet, Y., Le Roux, G., Campos, L., Dromelet, A., Lepelley, P., Jouault, H., Imbert, M., Rosenwadj, M., Vergé, V., Bissières, P., Raphaël, M., Béné, M.C. & Feuillard, J. (2002) Immunophenotypic clustering of myelodysplastic syndromes. Blood, 100, 23492356.
  • Medeiros, B.C., Kohrt, H.E., Arber, D.A., Bangs, C.D., Cherry, A.M., Majeti, R., Kogel, K.E., Azar, C.A., Patel, S. & Alizadeh, A.A. (2010) Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). Leukemia Research, 34, 594597.
  • Nakahata, T. & Okumura, N. (1994) Cell surface antigen expression in human erythroid progenitors: erythroid and megakaryocytic markers. Leukaemia & Lymphoma, 13, 401409.
  • Nakamura, K., Ogata, K., An, E. & Dan, K. (2000) Flow cytometric assessment of CD15+ CD117+ cells for the detection of minimal residual disease in adult acute myeloid leukaemia. British Journal of Haematology, 108, 710716.
  • Nomdedeu, J., Bussaglia, E., Villamor, N., Martinez, C., Esteve, J., Tormo, M., Estivill, C., Queipo, M.P., Guardia, R., Carricondo, M., Hoyos, M., Llorente, A., Juncà, J., Gallart, M., Domingo, A., Bargay, J., Mascaró, M., Moraleda, J.M., Florensa, L., Ribera, J.M., Gallardo, D., Brunet, S., Aventin, A. & Sierra, J., on behalf of the Spanish CETLAM (2010) Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size. Leukemia Research, 7, 7. [Epub ahead of print. doi: 10.1016/j.leukres.2010.05.015].
  • Ogata, K., Yokose, N., Shioi, Y., Ishida, Y., Tomiyama, J., Hamaguchi, H., Yagasaki, F., Bessyo, M., Sakamaki, H., Dan, K. & Kuriya, S. (2001) Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia. British Journal of Haematology. 115, 612615.
  • Ogata, K., Della Porta, M.G., Malcovati, L., Picone, C., Yokose, N., Matsuda, A., Yamashita, T., Tamura, H., Tsukada, J. & Dan, K. (2009) Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica, 94, 10661074.
  • Ommen, H.B., Nyvold, C.G., Braendstrup, K., Andersen, B.L., Ommen, I.B., Hasle, H., Hokland, P. & Ostergaard, M. (2008) Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. British Journal of Haematology, 141, 782791.
  • Paietta, E., Goloubeva, O., Neuberg, D., Bennett, J.M., Gallagher, R., Racevskis, J., Dewald, G., Wiernik, P.H. & Tallman, M.S. (2004) Eastern Cooperative Oncology Group. A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtype. Cytometry. Part B, Clinical Cytometry, 59, 19.
  • Pedreira, C.E., Costa, E.S., Arroyo, M.E., Almeida, J. & Orfao, A.A. (2008) Multidimensional classification approach for the automated analysis of flow cytometry data. IEEE Transactions on Biomedical Engineering, 55, 11551162.
  • Perea, G., Lasa, A., Aventín, A., Domingo, A., Villamor, N., Queipo de Llano, M.P., Llorente, A., Juncà, J., Palacios, C., Fernández, C., Gallart, M., Font, L., Tormo, M., Florensa, L., Bargay, J., Martí, J.M., Vivancos, P., Torres, P., Berlanga, J.J., Badell, I., Brunet, S., Sierra, J. & Nomdedéu, J.F.; Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel (2006) Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia, 20, 8794.
  • Pirruccello, S.J., Young, K.H. & Aoun, P. (2006) Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common. American Journal of Clinical Pathology, 125, 884894.
  • van der Pol, M.A., Broxterman, H.J., Pater, J.M., Feller, N., van der Maas, M., Weijers, G.W., Scheffer, G.L., Allen, J.D., Scheper, R.J., van Loevezijn, A., Ossenkoppele, G.J. & Schuurhuis, G.J. (2003) Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. Haematologica, 88, 134147.
  • Porwit-MacDonald, A., Björklund, E., Lucio, P., van Lochem, E.G., Mazur, J., Parreira, A., van den Beemd, M.W., van Wering, E.R., Baars, E., Gaipa, G., Biondi, A., Ciudad, J., van Dongen, J.J., San Miguel, J.F. & Orfao, A. (2000) BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia, 14, 8, 16125.
  • Raspadori, D.F., Lauria, M.A., Ventura, D., Rondelli, G., Visani de Vivo, A. & Tura, S. (1997) Incidence and prognostic relevance of CD34 expression in acute myeloid leukemia: analysis in 141 cases. Leukemia Research, 137, 966971.
  • Raspadori, D., Damiani, D., Lenoci, M., Rondelli, D., Testoni, N., Nardi, G., Sestigiani, C., Mariotti, C., Birtolo, S., Tozzi, M. & Lauria, F. (2001) CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia, 15, 11611164.
  • Raspadori, D., Damiani, D., Michieli, M., Stocchi, R., Gentili, S., Gozzetti, A., Masolini, P., Michelutti, A., Geromin, A., Fanin, R. & Lauria, F. (2002) PGP expression in acute myeloid leukemia: impact on clinical outcome. Haematologica, 87, 11351140.
  • van Rhenen, A., Feller, N., Kelder, A., Westra, A.H., Rombouts, E., Zweegman, S., van der Pol, M.A., Waisfisz, Q., Ossenkoppele, G.J. & Schuurhuis, G.J. (2005) High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clinical Cancer Research, 11, 65206527.
  • van Rhenen, A., van Dongen, G.A., Kelder, A., Rombouts, E.J., Feller, N., Moshaver, B., Stigter-van Walsum, M., Zweegman, S., Ossenkoppele, G.J. & Schuurhuis, G.J. (2007) The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood, 110, 26592666.
  • Rubnitz, J.E., Inaba, H., Dahl, G., Ribeiro, R.C., Bowman, W.P., Taub, J., Pounds, S., Razzouk, B.I., Lacayo, N.J., Cao, X., Meshinchi, S., Degar, B., Airewele, G., Raimondi, S.C., Onciu, M., Coustan-Smith, E., Downing, J.R., Leung, W., Pui, C.H. & Campana, D. (2010) Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. The Lancet Oncology, 11, 543552.
  • Saito, Y., Kitamura, H., Hijikata, A., Tomizawa-Murasawa, M., Tanaka, S., Takagi, S., Uchida, N., Suzuki, N., Sone, A., Najima, Y., Ozawa, H., Wake, A., Taniguchi, S., Shultz, L.D., Ohara, O. & Ishikawa, F. (2010) Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Science Translational Medicine, 3, 17ra9.
  • San Miguel, J.F., Martinez, A., Macedo, A., Vidriales, M.B., López-Berges, C., González, M., Caballero, D., García-Marcos, M.A., Ramos, F., Fernández-Calvo, J., Calmuntia, M.J., Diaz-Mediavilla, J. & Orfao, A. (1997) Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood, 90, 24652470.
  • San Miguel, J.F., Vidriales, M.B., Lopez Berges, C., Díaz-Mediavilla, J., Gutiérrez, N., Cañizo, C., Ramos, F., Calmuntia, M.J., Pérez, J.J., González, M. & Orfao, A. (2001) Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood, 98, 17461751.
  • Sanz, M.A., Grimwade, D., Tallman, M.S., Lowenberg, B., Fenaux, P., Estey, E.H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., Burnett, A.K. & Lo-Coco, F. (2009) Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemianet. Blood, 113, 18751891.
  • Satoh, C. & Ogata, K. (2008) Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes. Leukemia Research, 32, 699707.
  • Schnittger, S., Kern, W., Tschulik, C., Weiss, T., Dicker, F., Falini, B., Haferlach, C. & Haferlach, T. (2009) Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood, 114, 22202231.
  • Scott, B.L., Wells, D.A., Loken, M.R., Myerson, D., Leisenring, W.M. & Deeg, H.J. (2008) Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood, 112, 26812686.
  • Sievers, E.L., Lange, B.J., Alonzo, T.A., Gerbing, R.B., Bernstein, I.D., Smith, F.O., Arceci, R.J., Woods, W.G. & Loken, M.R. (2003) Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children’s Cancer Group study of 252 patients with acute myeloid leukemia. Blood, 101, 33983406.
  • Stachurski, D., Smith, B.R., Pozdnyakova, O., Andersen, M., Xiao, Z., Raza, A., Woda, B.A. & Wang, S.A. (2008) Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leukemia Research, 32, 215224.
  • Stetler-Stevenson, M., Arthur, D.C., Jabbour, N., Xie, X.Y., Molldrem, J., Barrett, A.J., Venzon, D. & Rick, M.E. (2001) Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood, 98, 979987.
  • van Stijn, A., Feller, N., Kok, A., van der Pol, M.A., Ossenkoppele, G.J. & Schuurhuis, G.J. (2005) Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis. Clinical Cancer Research, 11, 25402546.
  • Suzuki, R., Ohtake, S., Takeuchi, J., Nagai, M., Kodera, Y., Hamaguchi, M., Miyawaki, S., Karasuno, T., Shimodaira, S., Ohno, R., Nakamura, S. & Naoe, T. (2010) The clinical characteristics of CD7CD56+ acute myeloid leukemias other than M0. International Journal of Hematology, 91, 303309.
  • Swerdlow, S.H., Capo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (eds) (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon.
  • Taussig, D.C., Vargaftig, J., Miraki-Moud, F., Griessinger, E., Sharrock, K., Luke, T., Lillington, D., Oakervee, H., Cavenagh, J., Agrawal, S.G., Lister, T.A., Gribben, J.G. & Bonnet, D. (2010) Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(−) fraction. Blood, 115, 19761984.
  • Terwijn, M., Feller, N., van Rhenen, A., Kelder, A., Westra, A.H., Zweegman, S., Ossenkoppele, G. & Schuurhuis, G.J. (2009) Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. European Journal of Cancer, 45, 16921699.
  • Tiftik, N.Z., Bolaman, S., Batun, O., Ayyildiz, A., Isikdogan, A., Kadikoylu, G. & Muftuoglu, E. (2004) The importance of CD7 and CD56 antigens in acute leukaemias. International Journal of Clinical Practice, 58, 149152.
  • Valent, P., Horny, H.P., Bennett, J.M., Fonatsch, C., Germing, U., Greenberg, P., Haferlach, T., Haase, D., Kolb, H.J., Krieger, O., Loken, M., van de Loosdrecht, A., Ogata, K., Orfao, A., Pfeilstöcker, M., Rüter, B., Sperr, W.R., Stauder, R. & Wells, D.A. (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leukemia Research, 31, 727736.
  • Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellström-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937951.
  • van der Velden, V.H., Jacobs, D.C., Wijkhuijs, A.J., Comans-Bitter, W.M., Willemse, M.J., Hählen, K., Kamps, W.A., van Wering, E.R. & van Dongen, J.J. (2002) Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia, 16, 14321436.
  • van der Velden, V.H., van der Sluijs-Geling, A., Gibson, B.E., te Marvelde, J.G., Hoogeveen, P.G., Hop, W.C., Wheatley, K., Bierings, M.B., Schuurhuis, G.J., de Graaf, S.S., van Wering, E.R. & van Dongen, J.J. (2010) Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia, 24, 15991606.
  • Venditti, A.G., Del Poeta, F., Buccisano, A., Tamburini, M.C., Cox-Froncillo, MC., Aronica, G., Bruno, A., Del Moro, B., Epiceno, A.M., Battaglia, A., Forte, L., Postorino, M., Cordero, V. & Santinelli, S. (1998) Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia. Leukemia, 12, 10561063.
  • Venditti, A., Buccisano, F., Del Poeta, G., Maurillo, L., Tamburini, A., Cox, C., Battaglia, A., Catalano, G., Del Moro, B., Cudillo, L., Postorino, M., Masi, M. & Amadori, S. (2000) Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood, 96, 39483952.
  • Venditti, A., Maurillo, L., Buccisano, F., del Poeta, G., Mazzone, C., Tamburini, A., del Principe, M.I., Consalvo, M.I., de Fabritiis, P., Cudillo, L., Picardi, A., Franchi, A., Lo-Coco, F. & Amadori, S. (2003) Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia, 17, 21782182.
  • Voskova, D., Schoch, C., Schnittger, S., Hiddemann, W., Haferlach, T. & Kern, W. (2004) Stability of leukemia associated aberrant immunophenotypes in patients with acute leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic and molecular genetic findings. Cytometry, 62b, 2538.
  • Voskova, D., Schnittger, S., Schoch, C., Haferlach, T. & Kern, W. (2007) Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia. Leukaemia & Lymphoma, 48, 8088.
  • Wells, D.A., Benesch, M., Loken, M.R., Vallejo, C., Myerson, D., Leisenring, W.M. & Deeg, H.J. (2003) Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood, 102, 394403.
  • Westers, T.M., Alhan, C., Chamuleau, M.E., van der Vorst, M.J., Eeltink, C., Ossenkoppele, G.J. & van de Loosdrecht, A.A. (2010) Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood, 115, 17791784.
  • Yang, D.H., Lee, J.J., Mun, Y.C., Shin, H.J., Kim, Y.K., Cho, S.H., Chung, I.J., Seong, C.M. & Kim, H.J. (2007) Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 82, 15.